Inhalerx Ltd (ASX:IRX) CEO Darryl Davies speaks to Proactive's Thomas Warner about how the Australian healthcare company is positioned heading into 2023, and reveals what he believes investors can expect over the coming months.
Davies says that he is "hoping to have first patient in" for the company's Panic Disorder treatment around April 2023, with the same milestone for the Complex Regional Pain treatment to follow in the summer.